Audited Results as at 31.03.2026.
TRANSPEK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.0 pts less than Nifty Microcap 250 and 11.1 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transpek Industry Limited reported audited standalone results for FY2026 ending March 31, 2026. Revenue from operations declined to Rs. 62,119.90 lakhs from Rs. 64,985.31 lakhs in the previous year, representing a revenue decline of approximately 4.4%. Net profit (PAT) decreased to Rs. 4,564.81 lakhs from Rs. 4,874.07 lakhs, a decline of about 6.3%. Total comprehensive income fell significantly to Rs. 3,329.63 lakhs from Rs. 7,975.14 lakhs, primarily due to fair value losses on equity instruments. EBITDA margin remained stable at around 19%, showing cost efficiency despite lower volumes. Operating cash flow remained healthy at Rs. 7,847.14 lakhs. The Board recommended a dividend of Rs. 20 per share (200%). Auditors issued an unmodified (clean) opinion on both standalone and consolidated results.
The decline in revenue and profit is concerning for shareholders, though the stable EBITDA margin and strong operating cash flow provide some comfort. The clean audit opinion removes auditor-related concerns. The 200% dividend declaration signals management confidence despite the challenging year.